Objective To determine if MeDi modifies the time to clinical onset of HD ('phenoconversion') in premanifest carriers participating in Prospective Huntington At Risk Observational Study (PHAROS), and to examine the effects of BMI and caloric intake on time to phenoconversion. Design A prospective cohort study. Setting 41 Huntington Study Group sites in the US and Canada. 